Q2 2026 13F · SEC CIK 1958125

Catalio Capital Management, LP

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $532.1M
Reported positions: 39
Holdings vs S&P 500, 3 yrs: —
Assets under management: $2.2B

Catalio Capital Management, LP is a hedge fund that reported 39 positions worth $532.1M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Avalyn Pharmaceuticals Inc (AVLN, 10.4%), Johnson & Johnson (JNJ, 6.6%), Gilead Sciences (GILD, 6.4%).

Catalio Capital Management, LP holdings all 39 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Catalio Capital Management, LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
AVLNAvalyn Pharmaceuticals Inc	10.4%	New	1,675,830	—	$55.2M
JNJJohnson & Johnson	6.6%	New	138,946	—	$35.3M
GILDGilead Sciences	6.4%	4.8%	269,309	+64.3%	$34.0M
BBIOBridgebio Pharma Inc	6.4%	6.7%	455,041	+5.3%	$33.9M
SNDXSyndax Pharmaceuticals Inc	5.0%	5.1%	1,215,698	+16.5%	$26.6M
24477V105Definium Therapeutics Inc	5.0%	4.1%	562,672	-45.8%	$26.5M
BMYBristol-Myers Squibb Co Com	4.5%	5.3%	412,961	-1.8%	$23.8M
PBLSParabilis Medicines, Inc.	4.2%	New	824,043	—	$22.6M
NTRANatera Inc Com	4.2%	3.0%	82,181	+15.9%	$22.3M
INCYIncyte Corp	4.1%	3.6%	191,627	+5.2%	$21.7M
SEPNSepterna, Inc.	3.4%	1.5%	536,152	+82.1%	$18.0M
MLYSMineralys Therapeutics Inc	3.3%	2.5%	648,722	+47.8%	$17.5M
HTFLHeartflow Inc	3.2%	2.1%	583,055	+44.5%	$17.1M
CRVSCorvus Pharmaceuticals Inc Com	3.0%	2.7%	1,080,888	+21.2%	$16.1M
GPCRStructure Therapeutics Inc	2.8%	2.6%	276,550	+8.3%	$14.8M
PTGXProtagonist Therapeutics Inc	2.5%	New	106,799	—	$13.1M
IRONDisc Medicine Inc	2.2%	1.6%	159,384	+29.6%	$11.7M
EWEdwards Lifesciences Corp	2.1%	2.4%	124,778	-13.7%	$11.3M
AXSMAxsome Therapeutics Inc.	2.0%	New	43,182	—	$10.6M
RAREUltragenyx Pharmaceutical in	2.0%	3.7%	316,252	-62.8%	$10.6M
KLRAKailera Therapeutics Inc	1.9%	New	468,750	—	$10.3M
KPTIKaryopharm Therapeutics Inc	1.7%	1.0%	940,855	+4.8%	$9.2M
ODTXOdyssey Therapeutics, Inc.	1.6%	New	457,839	—	$8.6M
ASNDAscendis Pharma As Ord	1.6%	New	31,759	—	$8.5M
KARDKardigan Inc	1.4%	New	312,500	—	$7.5M
ELDNEledon Pharmaceuticals Inc	1.3%	1.1%	1,695,071	+3.4%	$6.7M
FDMT4d Molecular Therapeutics in	1.2%	New	471,254	—	$6.3M
MANEVeradermics Inc	1.1%	2.3%	45,856	-73.6%	$5.6M
DYNDyne Therapeutics Inc	1.0%	1.1%	244,929	-13.4%	$5.4M
GUTSFractyl Health Inc	0.9%	0.5%	6,168,749	+12.3%	$4.9M
IMCRImmunocore Hldgs PLC	0.9%	0.5%	148,045	+75.5%	$4.7M
DNTHDianthus Therapeutics Inc	0.6%	9.8%	32,941	-94.1%	$3.2M
BBOTBridgebio Oncology Therapeut	0.5%	New	318,407	—	$2.4M
TARAProtara Therapeutics Inc	0.4%	0.6%	520,148	-10.3%	$2.0M
HYPRHyperfine Inc	0.3%	0.3%	1,320,041	+0.0%	$1.8M
ATAIAtaibeckley Inc	0.2%	0.1%	196,858	+0.0%	$1.0M
MGXMetagenomi Therapeutics Inc	0.1%	0.1%	528,993	+0.0%	$630K
OMOutset Med Inc	0.1%	0.1%	118,279	+0.0%	$511K
SNSEFaeth Therapeutics Inc	0.1%	0.1%	14,718	+0.0%	$368K

What Catalio Capital Management, LP bought and sold in Q2 2026, against Q1 2026.

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +46.0% /yr; S&P 500 +20.1%
3 years: —
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$532.1M	39
Q1 2026	$478.7M	41
Q4 2025	$565.8M	45
Q3 2025	$540.9M	38
Q2 2025	$476.9M	40
Q1 2025	$403.4M	35
Q4 2024	$457.1M	33

Questions about Catalio Capital Management, LP's portfolio

What stocks does Catalio Capital Management, LP own?

Catalio Capital Management, LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 39 positions worth $532.1M. The largest are Avalyn Pharmaceuticals Inc (AVLN) at 10.4%, Johnson & Johnson (JNJ) at 6.6%, Gilead Sciences (GILD) at 6.4%, Bridgebio Pharma Inc (BBIO) at 6.4% and Syndax Pharmaceuticals Inc (SNDX) at 5.0%.

What did Catalio Capital Management, LP buy last quarter?

In Q2 2026, Catalio Capital Management, LP added a new position in Avalyn Pharmaceuticals Inc (AVLN), a new position in Johnson & Johnson (JNJ), a new position in Parabilis Medicines, Inc. (PBLS), a new position in Protagonist Therapeutics Inc (PTGX), a new position in Axsome Therapeutics Inc. (AXSM), Septerna, Inc. (SEPN) (+82.1% shares), Immunocore Hldgs PLC (IMCR) (+75.5% shares) and Gilead Sciences (GILD) (+64.3% shares), compared with its Q1 2026 filing.

What did Catalio Capital Management, LP sell last quarter?

In Q2 2026, Catalio Capital Management, LP sold all of Ascendis Pharma A/s, sold all of Terns Pharmaceuticals Inc (TERN), sold all of Soleno Therapeutics Inc (SLNO), sold all of Boston Scientific Corp (BSX), sold all of Cytokinetics Inc (CYTK), Dianthus Therapeutics Inc (DNTH) (-94.1% shares), Veradermics Inc (MANE) (-73.6% shares) and Ultragenyx Pharmaceutical in (RARE) (-62.8% shares), compared with its Q1 2026 filing.

When is Catalio Capital Management, LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Catalio Capital Management, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Catalio Capital Management, LP manage?

Catalio Capital Management, LP reported $2.2B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $532.1M.